Why 53.6% of GLP-1 Users Quit Within a Year (And How to Be in the Other Half)

Here is a number that should change how we talk about GLP-1 medications: 53.6% of people who start a GLP-1 receptor agonist for weight management discontinue within one year.

That figure comes from a January 2025 cohort study published in JAMA Network Open, which followed 125,474 US adults with overweight or obesity who were newly prescribed liraglutide, semaglutide, or tirzepatide between 2018 and 2023 (Rodriguez et al., 2025). By the two-year mark, that number climbed to 72.2%.

Let that sit for a moment. The medications we often describe as revolutionary — Ozempic, Wegovy, Mounjaro, Zepbound — are being abandoned by more than half the people who start them before they even finish a full year.

This is not a story about personal failure. It is a story about a gap between what these medications can do and the systems we build — or don't build — around them. And if you are on a GLP-1 or considering one, understanding this gap is the single most important thing you can do for your long-term success.

Why People Quit: What the Data Actually Shows

The reasons for GLP-1 discontinuation are more nuanced than "it didn't work" or "I couldn't handle the side effects." Research from multiple sources paints a picture with several overlapping drivers.

Side Effects

Gastrointestinal issues remain the most commonly reported reason for stopping. Across the broader population, side effects account for roughly 28% of all discontinuations (JAMA Network Open, 2024). The usual suspects — nausea, vomiting, constipation, diarrhea — are particularly common during dose escalation. Physicians report that nausea and vomiting drive nearly 44% of the discontinuation conversations they have with patients.

The irony is that most GI side effects are manageable and tend to diminish over time. But without guidance on how to navigate them, many people interpret early discomfort as a signal that the medication "isn't for them."

Cost and Insurance Gaps

Even in 2026, with Novo Nordisk's oral Wegovy pill now available at $149-$299/month depending on dose, cost remains a significant barrier. Only 13 state Medicaid programs cover GLP-1 medications for obesity. Medicare still does not. Private insurance coverage varies wildly, and prior authorization processes create friction that causes people to fall off treatment even when they are clinically responding.

Supply Shortages

The JAMA Network Open study specifically noted spikes in discontinuation that aligned with medication shortages — a 14.6% discontinuation peak in November 2023 corresponded with widely reported semaglutide supply issues.

Unrealistic Expectations

A Northwestern University analysis found that many patients begin GLP-1 therapy expecting the medication alone to produce lasting results (Northwestern, 2024). When weight loss plateaus — which it always does, on every intervention — or when the rate of loss slows after the first few months, the perception shifts from "this is working" to "this has stopped working."

Feeling "Done" Too Early

Some people reach a weight that feels satisfactory and discontinue, believing the job is finished. The data on what happens next is sobering.

Lack of Support Structure

This is the thread that runs through every other reason. Side effects feel insurmountable without guidance. Cost feels unjustifiable without visible progress. Plateaus feel like failure without context. GLP-1 persistence is not just a pharmacological question. It is a behavioral and structural one.

What STEP 4 Tells Us About Stopping

If there is one clinical trial that every GLP-1 user should understand, it is STEP 4.

Published in JAMA in 2021, the STEP 4 trial was a 68-week withdrawal study that asked a straightforward question: what happens when people who have been responding well to semaglutide stop taking it? (Rubino et al., 2021; PMID 33755728)

The design was elegant. After 20 weeks on semaglutide 2.4 mg, 803 participants who had reached the maintenance dose were randomized: two-thirds continued semaglutide, one-third switched to placebo. Both groups continued lifestyle intervention.

The results were unambiguous:

• Continued semaglutide group: Lost an additional 7.9% of body weight from week 20 to week 68.
• Switched-to-placebo group: Regained 6.9% of body weight over the same period.

That is a 14.8 percentage-point difference between continuing and stopping. The people who stayed on the medication kept losing. The people who stopped began regaining almost immediately — not because they lacked discipline, but because obesity is a chronic condition with biological drivers that do not pause when we feel we have made enough progress.

The STEP 1 extension trial reinforced this. In that study (Wilding et al., 2022; PMID 35441470), participants who had lost an average of 17.3% of their body weight on semaglutide over 68 weeks regained roughly two-thirds of that loss within one year of stopping — ending up with a net loss of only 5.6% from baseline. Cardiometabolic improvements, including blood pressure and lipid changes, also reverted toward baseline.

The message from the clinical evidence is clear: GLP-1 persistence matters. These medications treat an ongoing condition. Stopping them, in most cases, means the condition reasserts itself.

The Behavior Gap: Medications Create Opportunity, Not Organization

Here is the tension at the center of the GLP-1 conversation: these medications are remarkably effective at reducing appetite, quieting food noise, and creating a metabolic environment where weight loss is possible. But they do not build habits. They do not restructure your kitchen, your schedule, or your stress response. They do not teach you how to eat well when the nausea passes, or how to maintain movement patterns, or how to navigate a family dinner where every dish is a trigger.

A January 2026 article in Psychology Today put it this way: "GLP-1 medications can support readiness for change, but they do not replace the role of context. When environments reduce friction, support attention, and reinforce identity, habits are more likely to endure — even as motivation fluctuates" (Psychology Today, 2026).

This aligns with NICE Guideline NG246 on overweight and obesity management, which was updated in January 2026. The guideline places structured, ongoing behavioral support at the center of long-term obesity management — not as an add-on to pharmacotherapy, but as a core component (NICE NG246). It emphasizes personalized approaches, sustainable dietary changes, and routine follow-up. The guideline explicitly recognizes the chronic nature of obesity and the need for ongoing — not episodic — support.

There is a phrase that surfaces again and again in GLP-1 community discussions: "I need habits that survive without the prescription." Whether someone plans to stay on medication long-term or is using it as a bridge, the behavioral work matters either way. The medication gives you a window of reduced appetite and clearer decision-making. What you build during that window is what endures.

Evidence-Based Strategies for Staying on Track

GLP-1 adherence is not about white-knuckling your way through side effects. It is about building systems that make persistence the path of least resistance. Here are four practices grounded in clinical evidence.

Weekly Plateau Scoreboard

Weight loss is not linear, and a stalled scale does not mean a stalled journey. A weekly scoreboard across four behavioral anchors — hydration, protein intake, movement, and sleep quality — gives you a richer picture of what is actually happening.

Score each area on a simple 1-5 scale. Identify your lowest-scoring anchor each week. Then test one small adjustment for the next seven days. This approach is supported by meta-analytic evidence showing that behavioral weight management interventions targeting specific eating behavior traits — not just calorie restriction — produce meaningful improvements in uncontrolled eating, external eating, and overall dietary restraint (PMID 39719170).

The scoreboard reframes plateaus from "the medication isn't working" to "there is a specific behavior I can adjust." That shift in framing is protective against early discontinuation.

Rebound Early-Warning Threshold

The STEP 1 extension data (PMID 35441470) showed that weight regain after semaglutide withdrawal was not sudden — it was progressive. That pattern means there is a detection window if you are paying attention.

Define a personal weekly trend threshold — a specific amount of weight change over a rolling period that signals it is time to tighten up behaviors before the trend compounds. This is not about panicking over daily fluctuations. It is about having a pre-defined rule that removes emotional decision-making from the process. When the threshold is crossed, you know exactly which behaviors to audit first (refer back to your scoreboard).

Clinician Visit Question Stack

One of the most underutilized tools for GLP-1 persistence is structured communication with your prescribing clinician. Many people show up to appointments without a clear agenda, then leave with unanswered questions about side effects, dosing, or what to expect next.

Keep a running list of questions linked to specific symptoms, barriers, or patterns you have noticed. Before each visit, prioritize the top three. This practice, echoed by NHS guidance on semaglutide management, ensures that your limited appointment time addresses the issues most likely to derail your persistence.

Transition Baseline Logging

Dose changes — both increases and switches between medications (for example, moving from semaglutide to tirzepatide, or from injectable to oral Wegovy) — are high-risk moments for discontinuation. Side effects can resurface. Appetite patterns shift. Energy levels fluctuate.

A 14-day transition log that tracks appetite, GI symptoms, and energy patterns during these windows gives you and your clinician data to distinguish between temporary adjustment effects and genuine intolerance. Without this data, it is easy to conflate a rough transition with a reason to quit.

The Side Effect Strategy

Side effects are the single most cited reason for GLP-1 discontinuation. But most GI side effects are dose-dependent, transient, and manageable with specific dietary strategies. A 2023 multidisciplinary expert consensus on managing GLP-1-related GI adverse events (PMID 36614945) laid out practical recommendations that too few patients ever receive.

Fiber Ladder Progression

Constipation is common on GLP-1 therapy, particularly at higher doses. The instinct to dramatically increase fiber intake can backfire — too much fiber too quickly worsens bloating and gas. Instead, increase fiber gradually, adding one new source every three to four days and pairing each increase with additional water intake. Think of it as a ladder: start with cooked vegetables, then add whole grains, then legumes, then raw vegetables. Each rung needs a few days before you climb to the next.

Symptom-Day Simple Meals

On high-nausea days, switch to simpler, lower-fat meal patterns. Bland, easily digestible foods — rice, toast, bananas, clear broths — reduce gastric irritation. This is not about restricting long-term. It is about having a specific protocol for difficult days so that nausea does not spiral into skipped meals, dehydration, and a phone call to discontinue.

Hydration Checkpoint Anchors

Dehydration compounds nearly every GLP-1 side effect. The expert consensus recommends generous water intake throughout the day, but "drink more water" is vague enough to be useless as a behavior cue. Instead, anchor hydration to two fixed daily checkpoints: a full glass within 30 minutes of waking, and another before mid-afternoon. These are minimum thresholds, not targets — but they create structure that prevents the all-too-common pattern of reaching evening having barely hydrated.

Electrolyte Risk-Day Rule

On days with significant GI losses — diarrhea, vomiting — electrolyte support is not optional. Clinical guidance recommends supplementing with electrolytes on high-loss days to prevent the fatigue, dizziness, and general misery that drive acute discontinuation decisions. Keep an electrolyte solution accessible so that the barrier to using it is as low as possible.

The Cost and Access Reality

It would be dishonest to write about GLP-1 persistence without addressing cost. Even with the new oral Wegovy at $149/month for starter doses and $299/month for maintenance doses — and even with alternatives like compounded semaglutide available through platforms like Hims starting around $199/month — these medications remain expensive for many people, particularly without insurance coverage.

The coverage landscape in 2026 is improving but uneven. Private insurers increasingly cover GLP-1s for obesity, though often with prior authorization and step therapy requirements. Medicare still does not. Only 13 state Medicaid programs do. For many people, the cost question is not "can I afford this month" but "can I afford this indefinitely" — and the uncertainty itself becomes a reason to stop.

This is a real barrier, and it deserves systemic solutions that go beyond individual advice. What is within your control: talk to your prescriber about the full range of options (brand, generic, compounded, oral vs. injectable), explore manufacturer savings programs, and if cost forces a break in treatment, work with your clinician to build a plan for the transition rather than simply stopping.

What Persistence Really Means

There is a common misconception that GLP-1 persistence means perfect adherence — never missing a dose, never wavering, never questioning the choice. That is not what the research describes, and it is not a realistic standard for any chronic treatment.

Persistence, in the clinical literature, means staying connected to the treatment plan over time. It means returning after a missed dose. It means adjusting when side effects emerge rather than abandoning ship. It means building the behavioral scaffolding — the habits, the routines, the support systems — that make continuation feel sustainable rather than heroic.

The 46.4% who remain on GLP-1 therapy at the one-year mark are not more disciplined than the 53.6% who discontinue. The JAMA Network Open data shows that the factors associated with continuation were structural: weight loss progress (visible reinforcement), income (the ability to sustain cost), and the absence of unmanaged adverse events. In other words, the people who stayed had systems — clinical, financial, behavioral — that supported staying.

This is why the conversation about GLP-1 adherence cannot begin and end with the medication itself. Semaglutide and tirzepatide are extraordinary pharmacological tools. The Cleveland Clinic's overview describes how they mimic the GLP-1 hormone to reduce appetite, slow gastric emptying, and improve metabolic markers across multiple systems. But a tool is only as effective as the hand that holds it — and in this case, the "hand" is everything surrounding the prescription: the diet strategy, the side effect management plan, the cost coverage, the behavioral tracking, the clinical communication, the community support.

The Journey Ahead

The 53.6% discontinuation rate is not a verdict on GLP-1 medications. It is a verdict on the support structures we have built around them — which is to say, in many cases, the structures we have not built.

Every person who starts a GLP-1 is making a significant decision about their health. That decision deserves more than a prescription and a follow-up appointment in three months. It deserves a framework: a way to track what is working, anticipate what might not, manage the rough days with specific strategies, and stay connected to the reasons the journey began.

The question is not whether GLP-1s work. The research — from STEP 4 to the STEP 1 extension to the real-world data — is clear on that. The question is whether you will build the life that makes them worth continuing. The habits that sustain you on the medication. The systems that catch you during transitions. The awareness that persistence is not perfection — it is the quiet, repeated choice to stay in the process.

That is what it means to be in the other half.

---

Sources

• Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Network Open. 2025;8(1):e2457349. doi:10.1001/jamanetworkopen.2024.57349
• Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. PMID 33755728
• Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PMID 35441470
• Mechanick JI, Kushner RF, Sugerman HJ, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2023. PMID 36614945
• The impact of behavioral weight management interventions on eating behavior traits in adults with overweight or obesity: A systematic review and meta-analysis. 2024. PMID 39719170
• NICE Guideline NG246: Overweight and obesity management. Updated January 2026. nice.org.uk/guidance/ng246
• "Why Environment Matters More When Using GLP-1 Medications." Psychology Today. January 2026. psychologytoday.com
• Cleveland Clinic. GLP-1 Agonists: What They Are, How They Work & Side Effects. clevelandclinic.org
• UK Government / NHS. GLP-1 medicines for weight loss and diabetes: what you need to know. gov.uk